Posters
Effect of accelerated collagen corneal cross-linking in arresting the progression of keratoconus amongst young Omani population: one year follow-up results
Poster Details
First Author: A.Al Abri OMAN
Co Author(s): A. Al Augail N. Raj Mohan
Abstract Details
Purpose:
to assess the effect of accelerated collagen corneal cross linking( ACXL) in arresting the progression of keratoconus (KC) amongst young Omani population one year follows up results
Setting:
Armed force hospital (AFH) ophthalmology department, Muscat, Oman.
Methods:
A retrospective study comprising 158 eyes off 101 patients age 9-20 years , with progressive keratoconus were included in this study and underwent corneal topography for max K and spectral domain OCT( SD-OCT) for Pachymetry. Forme fruste KC ,Pullucid Marginal Degeneration and other corneal ectatic condition were excluded. All patients underwent Epithelium-Off ACXL using 0.1%Riboflavin that was administrated for 10 minutes after debridement of 7-8 mm of corneal epithelium .Cornea was exposed to 365 nm UVA light for 4 minutes at an irradiance of 30mW/cm2. Patients were followed up at 3 months and one year.
Results:
over the time period the mean change of reduction in k max after is -0.135 ( -0.150 ,-0.120) per month which is statistically significant, P < 0.001 . Best corrected visual acuity statistically no significant change ( -0.001 , 0.001 ). Corneal thickness over period of time the mean change -0.465(-0.588 , -0.342 ).
Conclusions:
ACXL, has shown significant effect in arresting the progression of keratoconus disease in our age group patients , also showed improvement by mean change -0.135 diopters of k max per month over period of time. Corneal thickness reduction even if it is statistically significant, the mean reduction of -.456 micrometer consider clinically stable cornea after ACXL. Fitting of the rigid gas permeable lens ,RGP , noted to be stable because of the flattening effect of CXL , so that��s why statistically no significant change but practically patient gain good and stable vision.
Financial Disclosure:
NONE
